Circulating angiopoietin-1 and angiopoietin-2 in critically ill patients: development and clinical application of two new immunoassays
-
* Corresponding author: Philipp Kümpers kuempers.philipp@mh-hannover.de
Critical Care 2008, 12:R94 doi:10.1186/cc6966
Accesses
- Last 30 days: 65 accesses
- Last year: 616 accesses
- All time: 2981 accesses
Cited by
BioMed Central: 4 citations
|
Commentary
Does low angiopoietin-1 predict adverse outcome in sepsis? Sascha David, Matijs van Meurs, Philipp Kümpers Critical Care 2010, 14:180 (20 July 2010) |
|
Research
Time course of angiopoietin-2 release during experimental human endotoxemia and sepsis Philipp Kümpers, Matijs van Meurs, Sascha David, Grietje Molema, Johan Bijzet, Alexander Lukasz, Frank Biertz, Hermann Haller, Jan G Zijlstra Critical Care 2009, 13:R64 (5 May 2009) |
|
Review
Bench-to-bedside review: Angiopoietin signalling in critical illness – a future target? Matijs van Meurs, Philipp Kümpers, Jack JM Ligtenberg, John HJM Meertens, Grietje Molema, Jan G Zijlstra Critical Care 2009, 13:207 (9 March 2009) |
|
Research
Philipp Kümpers, Alexander Lukasz, Sascha David, Rüdiger Horn, Carsten Hafer, Robert Faulhaber-Walter, Danilo Fliser, Hermann Haller, Jan T Kielstein Critical Care 2008, 12:R147 (21 November 2008) Excess circulating angiopoietin-2 was shown to correlate with severity of illness and tissue hypoxia, suggesting a potential role as a powerful independent biomarker of adverse clinical outcome in critically ill patients.
|
